| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADAM19 |
| Uniprot No | Q9H013 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-955aa |
| 氨基酸序列 | MPGGAGAARLCLLAFALQPLRPRAAREPGWTRGSEEGSPKLQHELIIPQWKTSESPVREKHPLKAELRVMAEGRELILDLEKNEQLFAPSYTETHYTSSGNPQTTTRKLEDHCFYHGTVRETELSSVTLSTCRGIRGLITVSSNLSYVIEPLPDSKGQHLIYRSEHLKPPPGNCGFEHSKPTTRDWALQFTQQTKKRPRRMKREDLNSMKYVELYLVADYLEFQKNRRDQDATKHKLIEIANYVDKFYRSLNIRIALVGLEVWTHGNMCEVSENPYSTLWSFLSWRRKLLAQKYHDNAQLITGMSFHGTTIGLAPLMAMCSVYQSGGVNMDHSENAIGVAATMAHEMGHNFGMTHDSADCCSASAADGGCIMAAATGHPFPKVFNGCNRRELDRYLQSGGGMCLSNMPDTRMLYGGRRCGNGYLEDGEECDCGEEEECNNPCCNASNCTLRPGAECAHGSCCHQCKLLAPGTLCREQARQCDLPEFCTGKSPHCPTNFYQMDGTPCEGGQAYCYNGMCLTYQEQCQQLWGPGARPAPDLCFEKVNVAGDTFGNCGKDMNGEHRKCNMRDAKCGKIQCQSSEARPLESNAVPIDTTIIMNGRQIQCRGTHVYRGPEEEGDMLDPGLVMTGTKCGYNHICFEGQCRNTSFFETEGCGKKCNGHGVCNNNQNCHCLPGWAPPFCNTPGHGGSIDSGPMPPESVGPVVAGVLVAILVLAVLMLMYYCCRQNNKLGQLKPSALPSKLRQQFSCPFRVSQNSGTGHANPTFKLQTPQGKRKVINTPEILRKPSQPPPRPPPDYLRGGSPPAPLPAHLSRAARNSPGPGSQIERTESSRRPPPSRPIPPAPNCIVSQDFSRPRPPQKALPANPVPGRRSLPRPGGASPLRPPGAGPQQSRPLAALAPKVSPREALKVKAGTRGLQGGRCRVEKTKQFMLLVVWTELPEQKPRAKHSCFLVPA |
| 预测分子量 | 104,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ADAM19重组蛋白的参考文献示例(注：以下内容为假设性示例，实际文献需通过学术数据库查询确认)：
---
1. **"Expression and functional characterization of recombinant ADAM19 metalloprotease"**
*Author: Shi Z, et al.*
摘要：本研究通过哺乳动物表达系统成功表达并纯化重组ADAM19蛋白，证实其具有金属蛋白酶活性，并发现其在体外能够切割特定细胞外基质蛋白，提示其在组织重塑中的潜在作用。
2. **"ADAM19 regulates cell migration through interaction with integrins"**
*Author: Lee H, et al.*
摘要：利用重组ADAM19胞外域蛋白进行功能实验，发现其通过结合β1整合素调控细胞黏附和迁移过程，为ADAM19在癌症转移中的作用提供了分子机制证据。
3. **"Structural insights into ADAM19 ectodomain by cryo-EM"**
*Author: Zhang Y, et al.*
摘要：通过冷冻电镜解析重组ADAM19胞外区的高分辨率结构，揭示了其催化结构域和跨膜信号调控域的构象变化，为靶向药物设计提供结构基础。
4. **"Role of recombinant ADAM19 in cardiovascular development"**
*Author: Tanaka M, et al.*
摘要：利用重组ADAM19蛋白进行斑马鱼胚胎实验，证明其在心脏发育过程中通过调节Notch信号通路影响心内膜垫的形成。
---
建议通过PubMed、Web of Science等平台以关键词“ADAM19 recombinant protein”或“ADAM19 expression”检索真实文献。
ADAM19 (A Disintegrin and Metalloproteinase 19) is a member of the ADAM family of transmembrane proteins, which are characterized by their dual roles in proteolysis and cell adhesion. First identified in the late 1990s, ADAM19 is a multidomain protein consisting of a prodomain, metalloproteinase, disintegrin-like, cysteine-rich, transmembrane, and cytoplasmic tail regions. Its metalloproteinase domain enables enzymatic activity, while the disintegrin and cysteine-rich domains mediate interactions with extracellular matrix components and cell-surface receptors.
Functionally, ADAM19 plays critical roles in ectodomain shedding, cleaving substrates such as growth factors (e.g., neuregulins) and cytokine receptors, thereby regulating cellular signaling pathways. It is involved in developmental processes, including cardiovascular and skeletal formation, as demonstrated by studies in ADAM19-deficient mice showing heart valve defects and impaired neural crest cell migration. In humans, ADAM19 is implicated in pathological conditions such as cancer progression, inflammation, and cardiovascular diseases. For example, its overexpression in tumors correlates with enhanced metastasis via modulation of cell adhesion and growth factor signaling.
Recombinant ADAM19 proteins, typically produced in mammalian expression systems, retain enzymatic activity and structural domains for in vitro studies. These tools are essential for investigating substrate specificity, inhibitor screening, and mechanistic studies of ADAM19-related diseases. Researchers also utilize recombinant ADAM19 to explore its interactions with integrins or other ligands, offering insights into its role in cell-cell communication. As a therapeutic target, ADAM19 inhibition is being explored in oncology and inflammatory disorders, though challenges remain in balancing specificity and off-target effects. Ongoing research aims to unravel its complex biology and translational potential.
×
